These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 29924853)

  • 1. Optical coherence tomography findings as a predictor of clinical course in patients with branch retinal vein occlusion treated with ranibizumab.
    Shiono A; Kogo J; Sasaki H; Yomoda R; Jujo T; Tokuda N; Kitaoka Y; Takagi H
    PLoS One; 2018; 13(6):e0199552. PubMed ID: 29924853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macular vessel reduction as predictor for recurrence of macular oedema requiring repeat intravitreal ranibizumab injection in eyes with branch retinal vein occlusion.
    Hasegawa T; Takahashi Y; Maruko I; Kogure A; Iida T
    Br J Ophthalmol; 2019 Oct; 103(10):1367-1372. PubMed ID: 30514711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion.
    Kim M; Yu SY; Kim ES; Bae SH; Park JH; Yu HG; Kwak HW
    Ophthalmologica; 2012; 227(3):132-8. PubMed ID: 22212151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimodal imaging to distinguish microvascular and morphological changes in retinal vein occlusion after intravitreal ranibizumab with or without triamcinolone acetonide injection.
    Wang N; Zou J; Li S; Deng X; Zeng J; Ding C
    BMC Ophthalmol; 2024 Aug; 24(1):354. PubMed ID: 39164640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of one and three initial monthly intravitreal ranibizumab injection in patients with macular edema secondary to branch retinal vein occlusion.
    Bayat AH; Çakır A; Özturan ŞG; Bölükbaşı S; Erden B; Elçioğlu MN
    Int J Ophthalmol; 2018; 11(9):1534-1538. PubMed ID: 30225230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twenty-Four Month Results of Intravitreal Ranibizumab for Macular Edema after Branch Retinal Vein Occlusion: Visual Outcomes and Resolution of Macular Edema.
    Inagaki M; Hirano Y; Yasuda Y; Kawamura M; Suzuki N; Yasukawa T; Yoshida M; Ogura Y
    Semin Ophthalmol; 2021 Oct; 36(7):482-489. PubMed ID: 33617388
    [No Abstract]   [Full Text] [Related]  

  • 7. Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion.
    Yiu G; Welch RJ; Wang Y; Wang Z; Wang PW; Haskova Z
    Ophthalmol Retina; 2020 Jan; 4(1):67-76. PubMed ID: 31669329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion.
    Nishimura T; Machida S; Tada A; Oshida E; Muto T
    Doc Ophthalmol; 2019 Aug; 139(1):67-74. PubMed ID: 30980231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing ranibizumab, dexamethasone implant, and combined therapy for macular edema secondary to branch retinal vein occlusion: a clinical trial.
    Meng L; Yang M; Jiang X; Li Y; Han X
    Int Ophthalmol; 2024 Jun; 44(1):262. PubMed ID: 38913192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER.
    Tadayoni R; Waldstein SM; Boscia F; Gerding H; Pearce I; Priglinger S; Wenzel A; Barnes E; Gekkieva M; Pilz S; Monés J;
    Ophthalmology; 2016 Jun; 123(6):1332-44. PubMed ID: 27039022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time course of changes in contrast sensitivity following intravitreal ranibizumab injection for branch retinal vein occlusion.
    Sugiura Y; Okamoto F; Murakami T; Morikawa S; Hiraoka T; Oshika T
    Jpn J Ophthalmol; 2020 Sep; 64(5):497-505. PubMed ID: 32691257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectral-domain optical coherence tomography (SD-OCT) patterns and response to intravitreal bevacizumab therapy in macular edema associated with branch retinal vein occlusion.
    Kang HM; Chung EJ; Kim YM; Koh HJ
    Graefes Arch Clin Exp Ophthalmol; 2013 Feb; 251(2):501-8. PubMed ID: 22653439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal PRN ranibizumab treatment for macular edemadue to branch retinal vein occlusion.
    Çakmak HB; Arikan Yorgun M; Toklu Y; Mutlu M
    Turk J Med Sci; 2017 Feb; 47(1):40-46. PubMed ID: 28263518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANIBIZUMAB FOR MACULAR EDEMA AFTER BRANCH RETINAL VEIN OCCLUSION: One Initial Injection Versus Three Monthly Injections.
    Miwa Y; Muraoka Y; Osaka R; Ooto S; Murakami T; Suzuma K; Takahashi A; Iida Y; Yoshimura N; Tsujikawa A
    Retina; 2017 Apr; 37(4):702-709. PubMed ID: 27471827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
    Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
    Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectral-Domain Optical Coherence Tomography-Driven Treat-and-Extend and Pro Re Nata Regimen in Patients with Macular Oedema due to Retinal Vein Occlusion: 24-Month Evaluation and Outcome Predictors.
    Guichard MM; Xavier AR; Türksever C; Pruente C; Hatz K
    Ophthalmic Res; 2018; 60(1):29-37. PubMed ID: 29566387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Foveal Thickness Fluctuation in Anti-VEGF Treatment for Branch Retinal Vein Occlusion: A Long-term Study.
    Nagasato D; Muraoka Y; Tanabe M; Nishigori N; Osaka R; Mitamura Y; Tabuchi H; Kadomoto S; Murakami T; Ooto S; Suzuma K; Tsujikawa A
    Ophthalmol Retina; 2022 Jul; 6(7):567-574. PubMed ID: 35218996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Choroidal Thickness, Foveal Avascular Zone, and Macular Capillary Density in Macular Edema Secondary to Branch Retinal Vein Occlusion Treated with Ranibizumab or Aflibercept-A Prospective Study.
    Huang YT; Wang I; Lin CJ; Lai CT; Hsia NY; Chen HS; Tien PT; Bair H; Lin JM; Chen WL; Chen CH; Wu WC; Tsai YY
    Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIME COURSE OF CHANGES IN METAMORPHOPSIA FOLLOWING INTRAVITREAL RANIBIZUMAB INJECTION FOR BRANCH RETINAL VEIN OCCLUSION.
    Sugiura Y; Okamoto F; Morikawa S; Okamoto Y; Hiraoka T; Oshika T
    Retina; 2018 Aug; 38(8):1581-1587. PubMed ID: 28614133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between short- and long-term effects of intravitreal ranibizumab therapy on macular edema after branch retinal vein occlusion: a prospective observational study.
    Minami Y; Nagaoka T; Ishibazawa A; Yoshida A
    BMC Ophthalmol; 2017 Jun; 17(1):90. PubMed ID: 28610573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.